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Background  
The UK is considered to be the world leader in Non Medical Prescribing (NMP) practice and although 
growth is evident elsewhere (Australia, Canada, New Zealand and the United States) no other 
country has the same extended non-medical prescribing rights as the UK 
1
. There are now 54,000 
nurse and midwife prescribers across the UK prescribing over 12.8 million items per year. 
2
  Arguably 
this growth has outpaced research to evaluate the clinical and economic value of NMP. 
The legislative changes have taken place over a 15 year period, reflecting a consistent cautious 
evolution of the role, by 2006 almost all the British National Formulary was opened up to nurse 
prescribers with the restriction of some controlled drugs. In April 2012 further legislation 
3
 enabled 
NMPs to prescribe controlled drugs within their competence. Essentially nurses with a NMP 
qualification now have the same prescribing capabilities as doctors.  
Guidance on implementing NMP 
4
 predicted benefits would be; improved patient care without 
comproŵŝƐŝŶŐƐĂĨĞƚǇ ?ŝŵƉƌŽǀĞĚĂĐĐĞƐƐƚŽŵĞĚŝĐŝŶĞƐ ?ďĞƚƚĞƌƵƐĞŽĨŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůƐ ?ƐŬŝůůƐ
and more flexible team working across the NHS.  Whilst some of these benefits have been 
substantiated through research, there is still relatively little empirical evidence to support clinical 
and economic outcomes. 
5
 This is particularly true of evaluations of NMP in specialist palliative care 
settings 
6
, we identified only one previous national survey of NMP in palliative care 
7 
conducted in 
2005, and limited to community palliative care nurses.  
   
NMP in a palliative care context may be one mechanism through which people can be supported to 
remain at home with well controlled symptoms at the end of life. For example, patients with cancer 
typically spend 65-80% of their last 6 months of life at home and adequate pain control is often 
hindered by poor access to effective timely analgesia. These patients often have multiple, rapidly 
changing symptoms requiring highly specialist management.
8
   The h< ?ƐEursing and Midwifery 
Council accredited independent prescribing course consists of 26 days teaching and learning and a 
minimum of 12 days in practice under the supervision of a designated medical practitioner.  
 
Aim 
To explore the barriers to becoming a qualified NMP, ŝŶǀĞƐƚŝŐĂƚĞEDWƐ ?experiences of the transition 
from qualifying as a prescriber to prescribing in a palliative care context, determine the range of 
medicines nurses prescribe for cancer pain and establish the impact on practice of the 2012 NMP 
legal changes
3
.  
Design  
An online survey was designed using SurveyMonkey software and  consisting of  9 sections;  general 
information, experiences before, during and after the prescribing course, prescribing practice, 
clinical governance and risk management, prescribing for pain in palliative care, opinions about 
independent prescribing and views on support and continuing professional development. The pilot 
testing indicated the survey would take less than 20 minutes to complete. 
 
Participants  
The participants were nurse members of a regional cancer network palliative care group (n=61).  
The maximum number of questions was 55 (for respondents who were currently prescribing) and 
the minimum number was 7 (respondents who were not qualified prescribers). The draft 
questionnaire was reviewed by a small group of specialist cancer nurses to enhance content and 
face validity.  The link to the online survey was circulated by email during May and June 2013 and 
was followed up with a reminder email 2 weeks later. Ethics committee approval was obtained for 
this study (ref: HSLTLM/12/067). The survey responses were exported to SPSS for analysis and free 
text responses were analysed by theme and categorized.   
 
Results  
A 61% (n=37) response rate was obtained. The majority of respondents were clinical nurse 
specialists in palliative care (n=27; 75%). Other respondents were advanced nurse practitioners (n=3; 
8%), or senior nurses with management or educational roles within palliative care settings (n=6; 
17%). Most (n=26; 70%) worked full time and most respondents (n=31;84% ) were aged between 41 
and 55 years. Three (8%) were less than 40 years of age and three (8%)were 56 years of age or older.   
 
Nurse prescribers  
14 (38%) respondents were qualified independent prescribers and currently prescribing, three (5%) 
were currently training, three (8%) were recently qualified and waiting to start prescribing and 18 
(49%) were not qualified as independent prescribers. Of the respondents who were qualified 
prescribers, six (33%) had qualified within the last 2 years, six (33%) qualified 3-4 years ago, and five 
(28%) 6-7 years ago. One respondent had been qualified for 9 years.  28 (78%) respondents reported 
a non-medical prescribing qualification is relevant to their current role.   
 
Non prescribers  
Of the non prescribers (n=18), two (13%) were already either enrolled on or planning to undertake 
the course in the near future, six (40%) reported they did not perceive a need for the qualification 
and four (27%) reported being constrained by lack of time. A small number of respondents (n=3; 
20%) explained they would be motivated to become a prescriber by a financial incentive such as a 
pay rise or promotion or if the prescribing course was part of a recognised broader academic 
qualification.          
     
Decision to undertake the prescribing course 
 12 (63%) reported it was entirely their own decision to undertake the course and five had made the 
decision jointly with their employer. No respondents reported they became a prescriber solely at 
ƚŚĞŝƌĞŵƉůŽǇĞƌ ?ƐƌĞƋƵĞƐƚ ?All respondents were motivated to undertake the course by the belief it 
would increase the quality of existing patient care and make patient access to medicines quicker and 
more efficient.  
 
Transition to prescribing  
Only three (31%) of the 14 respondents currently prescribing  started prescribing within 2 months of 
qualifying and 8 (57%) were delayed by between two and four months, with the longest reported 
delay of over six months in one case. On completion of the course, only one respondent said they 
felt completely prepared to prescribe. Concerns about prescribing related to a lack of confidence 
(n=5;36%), a fear of making a prescribing error (n=2;14%), lack of GP support (n=2;14%) and lack of 
peer or management support (n=2;14%).   
 
Prescribing practice 
In terms of prescribing specific to cancer pain, all respondents reported they were prepared to 
initiate an oral opioid, a subcutaneous infusion and adjuvant pain treatment such as gabapentin or 
carbamazepine. Most (n=12; 86%) reported that the change in controlled drugs legislation had 
positively influenced their practice. DŽƐƚƉƌĞƐĐƌŝďŝŶŐƚŽŽŬƉůĂĐĞŝŶĂƉĂƚŝĞŶƚ ?ƐŚŽŵĞ(n=9; 64%) or 
inpatient setting (n=6; 43%). Less prescribing was undertaken in outpatient clinics (n=3;21%) or 
hospice settings (n=1;7%) .  
 
Insert table on analgesics and associated medicines prescribed for cancer pain.  (Table 1) 
 
Discussion 
 
This survey was distributed 12 months after the legislation permitting the prescribing of controlled 
drugs 
3
. It differs from previous NMP surveys in that it focuses on nurses working in palliative care 
and incorporates the views of both non prescribers and prescribers.  In terms of barriers to 
becoming a prescriber several non-ƉƌĞƐĐƌŝďĞƌƐĐŝƚĞĚ ‘ůĂĐŬŽĨƚŝŵĞ ?.    Support through adequate study 
leave and covering current work load may help overcome this.  Whilst the extensive range of drugs 
NMPs prescribe for cancer pain is apparent in Table 1 it perhaps belies the fact that only a minority 
of qualified prescribers felt completely prepared to prescribe on completing the course. This is in line 
with previous findings 
1 8 9
 ƚŚĂƚĞǆƉĞƌŝĞŶĐĞŚĞůƉƐƚŽŵĂǆŝŵŝƐĞƚŚĞƉƌĞƐĐƌŝďĞƌ ?ƐƌŽůĞ and reinforces the 
requirement for ongoing support and mentorship.  Concern has been expressed previously 
10
 about 
the economic implications of training prescribers who do not go on to prescribe; in 2007 over 50% of 
community palliative care qualified NMPs were not actually prescribing 
7
. In contrast no qualified 
ƉƌĞƐĐƌŝďĞƌƐŝŶŽƵƌƐƵƌǀĞǇĨĞůůŝŶƚŽƚŚĞ ‘ŶĞǀĞƌƉƌĞƐĐƌŝďĞĚ ?Žƌ ‘ƐƚŽƉƉĞĚƉƌĞƐĐƌŝďŝŶŐ ?ĐĂƚĞŐŽƌŝĞƐ which 
suggests support and mentorship may be particularly strong within our surveyed population. Of 
concern however were reported delays between qualifying as a prescriber and actually prescribing. 
This delay should be addressed to maximise value and ensure skills learned are translated into 
practice within reasonable time frames. The concerns expressed by NMPs in previous surveys 
regarding prescribing opioids
11 12
 were not represented here. This suggests the legislative changes 
were well timed to coincide with a sense of readiness among nurses to take on this extension to 
their role. This study has limitations, it is a small scale survey of the membership of one regional 
palliative care nurses group within the UK and our findings therefore may not be representative of 
all nurse prescribers working in palliative care. We were unable to obtain information on non-
responders so differences between responders and non- responders could not be explored.  
Conclusion  
Whilst this survey found NMPs have embraced the 2012 legislative changes to prescribing and 
clearly prescribe a wide range of drugs for cancer pain previously unavailable to them, we also 
identified scope to improve the transition from qualified to active NMP by reducing the time interval 
between the two. Nurses who may be considering training to be a NMP may be encouraged by the 
provision of adequate study leave and support to cover clinical work.  Further research should 
ĞǆƉůŽƌĞƚŚĞƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞof NMP and economic implications.    
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Table 1 Analgesics prescribed for cancer pain  n=14  
 
Frequency  
± at least once a 
week ± 
at least once a 
month ± 
at least once every 
3 months ± 
less than once 
every 3 months ± 
Total 
± 
Laxatives  57.14% 8  
42.86% 
6  
0% 
0  
0% 
0  14  
Anti-emetics  64.29% 9  
28.57% 
4  
7.14% 
1  
0% 
0  14  
Paracetamol  57.14% 8  
28.57% 
4  
14.29% 
2  
0% 
0  14  
Ibuprofen (200mg or 400mg)  0% 0  
84.62% 
11  
0% 
0  
15.38% 
2  13  
Topical Capsaicin  0% 0  
0% 
0  
11.11% 
1  
88.89% 
8  9  
Codeine  0% 0  
41.67% 
5  
16.67% 
2  
41.67% 
5  12  
Codeine and paracetamol  15.38% 2  
38.46% 
5  
23.08% 
3  
23.08% 
3  13  
Dihydrocodeine  0% 0  
14.29% 
1  
0% 
0  
85.71% 
6  7  
Dihydrocodeine and paracetamol  0% 0  
0% 
0  
16.67% 
1  
83.33% 
5  6  
Codeine and ibuprofen  0% 0  
0% 
0  
33.33% 
2  
66.67% 
4  6  
Buprenorphine  0% 0  
41.67% 
5  
16.67% 
2  
41.67% 
5  12  
Tramadol  0% 0  
25% 
2  
12.50% 
1  
62.50% 
5  8  
Pethidine  0% 0  
0% 
0  
0% 
0  
100% 
5  5  
Meptazinol  16.67% 1  
0% 
0  
0% 
0  
83.33% 
5  6  
Tapentadol  16.67% 1  
16.67% 
1  
0% 
0  
66.67% 
4  6  
Diamorphine  27.27% 3  
45.45% 
5  
18.18% 
2  
9.09% 
1  11  
Morphine  53.85% 7  
23.08% 
3  
15.38% 
2  
7.69% 
1  13  
Oxycodone  41.67% 5  
41.67% 
5  
16.67% 
2  
0% 
0  12  
Fentanyl  0% 0  
42.86% 
6  
42.86% 
6  
14.29% 
2  14  
Hydromorphone  20% 1  
0% 
0  
0% 
0  
80% 
4  5  
Buprenorphine  11.11% 1  
33.33% 
3  
33.33% 
3  
22.22% 
2  9  
Pentazocine  0% 0  
0% 
0  
0% 
0  
100% 
5  5  
Dipipanone (with cyclizine)  0% 0  
0% 
0  
20% 
1  
80% 
4  5  
Papaveretum  0% 0  
0% 
0  
0% 
0  
100% 
5  5  
NSAID  30.77% 4  
46.15% 
6  
23.08% 
3  
0% 
0  13  
Amitriptyline, Nortriptyline, Pregabalin, Gabapentin, 
Duloxetine, Carbamazipine (200mg)  
16.67% 
2  
50% 
6  
25% 
3  8.33%  
 
 
 
 
 
